FR16C0004I1 - Composes cepheme - Google Patents

Composes cepheme

Info

Publication number
FR16C0004I1
FR16C0004I1 FR16C0004C FR16C0004I1 FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1 FR 16C0004 C FR16C0004 C FR 16C0004C FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1
Authority
FR
France
Prior art keywords
cephem compounds
cephem
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR16C0004I1 publication Critical patent/FR16C0004I1/fr
Application granted granted Critical
Publication of FR16C0004I2 publication Critical patent/FR16C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR16C0004C 2002-10-30 2016-02-03 Composes cepheme Active FR16C0004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (fr) 2002-10-30 2003-10-27 Composes cepheme

Publications (2)

Publication Number Publication Date
FR16C0004I1 true FR16C0004I1 (fr) 2016-03-25
FR16C0004I2 FR16C0004I2 (fr) 2017-01-06

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0004C Active FR16C0004I2 (fr) 2002-10-30 2016-02-03 Composes cepheme

Country Status (20)

Country Link
US (2) US7129232B2 (fr)
EP (1) EP1556389B9 (fr)
JP (1) JP4448821B2 (fr)
KR (1) KR101023035B1 (fr)
AR (1) AR041729A1 (fr)
AT (1) ATE368042T1 (fr)
BE (1) BE2016C002I2 (fr)
BR (1) BRPI0315188B8 (fr)
CA (1) CA2504730C (fr)
DE (1) DE60315178T3 (fr)
DK (1) DK1556389T6 (fr)
ES (1) ES2290498T7 (fr)
FR (1) FR16C0004I2 (fr)
HK (1) HK1086566A1 (fr)
HU (1) HUS1600008I1 (fr)
LU (1) LU92943I2 (fr)
NL (1) NL300793I1 (fr)
PT (1) PT1556389E (fr)
TW (1) TWI319403B (fr)
WO (1) WO2004039814A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529887A (en) * 2001-05-01 2005-05-27 Fujisawa Pharmaceutical Co Cephem compounds
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2007119511A1 (fr) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
US8883772B2 (en) 2007-10-09 2014-11-11 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
RU2606131C2 (ru) * 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
JP6151257B2 (ja) 2011-09-09 2017-06-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 肺内感染症の治療方法
EP2628730B1 (fr) * 2012-02-16 2017-12-06 Noxell Corporation Synthèse télescopique des sels de 5-amino-4-nitroso-1-alkyl-1h-pyrazole
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
JP6186001B2 (ja) 2012-09-27 2017-08-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． タゾバクタムアルギニン抗菌性組成物
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140274999A1 (en) * 2013-03-14 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3100732A1 (fr) * 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Compositions antibiotiques de ceftolozane
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
HUE045340T2 (hu) 2014-05-15 2019-12-30 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor
CN106795175A (zh) 2014-08-15 2017-05-31 默沙东公司 头孢菌素化合物的合成
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
WO2016028670A1 (fr) * 2014-08-18 2016-02-25 Merck Sharp & Dohme Corp. Formes salines de ceftolozane
WO2016095860A1 (fr) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Composés sous forme de dérivés d'acide pyrazolyl-carboxylique et de pyrazolyl-urée
WO2016100897A1 (fr) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Composés dérivés de l'acide thiadiazolyl-oxyminoacétique
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
US10214543B2 (en) 2014-12-30 2019-02-26 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
ES2729026T3 (es) 2015-06-29 2019-10-29 Sandoz Ag Procedimiento para la preparación de derivados de carbamoilamino pirazol
WO2017042188A1 (fr) 2015-09-08 2017-03-16 Sandoz Ag Procédé de préparation de ceftolozane à partir d'un acide 7-aminocéphalosporanique (7-aca)
WO2017096472A1 (fr) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Composés de céphème, leur préparation et utilisation
CN109195967A (zh) 2016-06-06 2019-01-11 默沙东公司 头孢洛扎的固体形式和制备方法
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (fr) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Polythérapies pour agents pathogènes résistant aux médicaments multiples
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (fr) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (fr) * 1986-09-22 1991-12-31 Takao Takaya Composes de cephem et procede de preparation
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
NZ529887A (en) * 2001-05-01 2005-05-27 Fujisawa Pharmaceutical Co Cephem compounds
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen

Also Published As

Publication number Publication date
HK1086566A1 (en) 2006-09-22
HUS1600008I1 (hu) 2016-03-29
DE60315178T2 (de) 2008-04-30
WO2004039814A1 (fr) 2004-05-13
NL300793I2 (fr) 2016-03-15
NL300793I1 (fr) 2016-03-15
JP4448821B2 (ja) 2010-04-14
US20070037786A1 (en) 2007-02-15
DK1556389T3 (da) 2007-11-26
AR041729A1 (es) 2005-05-26
ATE368042T1 (de) 2007-08-15
US7129232B2 (en) 2006-10-31
BR0315188A (pt) 2005-09-06
EP1556389B1 (fr) 2007-07-25
BRPI0315188B1 (pt) 2017-04-25
DE60315178D1 (de) 2007-09-06
EP1556389B3 (fr) 2015-04-01
LU92943I2 (fr) 2016-03-14
TW200410977A (en) 2004-07-01
KR20050084897A (ko) 2005-08-29
PT1556389E (pt) 2007-11-08
FR16C0004I2 (fr) 2017-01-06
BRPI0315188B8 (pt) 2021-05-25
ES2290498T7 (es) 2015-07-10
BE2016C002I2 (fr) 2023-03-07
JP2006506459A (ja) 2006-02-23
DK1556389T6 (da) 2015-05-11
CA2504730A1 (fr) 2004-05-13
EP1556389B9 (fr) 2015-09-09
TWI319403B (en) 2010-01-11
CA2504730C (fr) 2011-04-12
DE60315178T3 (de) 2015-06-18
US20040132994A1 (en) 2004-07-08
KR101023035B1 (ko) 2011-03-24
EP1556389A1 (fr) 2005-07-27
ES2290498T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
FR16C0004I2 (fr) Composes cepheme
MA27105A1 (fr) Nouveaux composes
NO20034108D0 (no) Rörkoplingsarrangement
DE60312848D1 (de) Verbindungsanschluss
NO20044046L (no) Substituerte hydroksyetylaminer
IS7381A (is) Efnasambönd
DE60326590D1 (de) Tend lamotrigin
ATE463248T1 (de) Cephem-verbindungen
IS7414A (is) Oxó-azabísýklísk efnasambönd
FI20021184A (fi) Lignaanivalmisteita
FI20020700A0 (fi) Sähkösuodatinrakenne
NO20045659L (no) Forbindelser
NO20031114D0 (no) Signallys
ATE318269T1 (de) Cephem-verbindungen
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60304268D1 (de) Bitmapdekomprimierung
DE50308979D1 (de) Einspritzventil
DE50310701D1 (de) Magnetfuehrungseinrichtung
FR2839740B3 (fr) Bourrelet perfectionne
ATE396192T1 (de) N-sulfonylaminothiazole
FI20020915A (fi) Viira
DE50306228D1 (de) Substituierte benzdioxepine
ATE327239T1 (de) Cephalosporine
AT5889U3 (de) Brennholzspleisser
FI20020958A (fi) Käsihihnasovitelma